DRUG · Mapped RxNorm record
daraxonrasib
Normalized identity: daraxonrasib View linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NCT06881784
Study summary
ClinicalTrials.govStudy of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE3
Loading study purpose, treatment groups and outcomes…
View the complete registry record, eligibility and contacts at ClinicalTrials.gov
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
docetaxel
Normalized identity: docetaxel View linked drug · Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Advertisement
Conditions
NSCLCverified · MONDO: non-small cell lung carcinoma
NSCLC (Non-small Cell Lung Carcinoma)unresolved
Interventions
daraxonrasibDRUG · verified · RxNorm: daraxonrasib
docetaxelDRUG · verified · RxNorm: docetaxel
Sponsors & collaborators
Revolution Medicines, Inc.lead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT06881784 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.